Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN

Oncotarget

Volumn 6, Issue 17, 2015, Pages 15137-15149

  Li, Hua ^a   Mohamed, Ahmed A ^a   Sharad, Shashwat ^a   Umeda, Elizabeth ^a   Song, Yingjie ^a   Young, Denise ^a   Petrovics, Gyorgy ^a   McLeod, David G ^a,b   Sesterhenn, Isabell A ^c   Sreenath, Taduru ^a   Dobi, Albert ^a   Srivastava, Shiv ^a  

^a Uniformed Services University of the Health Sciences   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c JOINT PATHOLOGY CENTER   (United States)

Author keywords

Androgen receptor; Enzalutamide; NEDD4; PMEPA1; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANILIDE; ANTIANDROGEN; BICALUTAMIDE; ENZALUTAMIDE; ESCRT PROTEIN; MEMBRANE PROTEIN; NEDD4 UBIQUITIN PROTEIN LIGASES; NITRILE; PHENYLTHIOHYDANTOIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PMEPA1 PROTEIN, HUMAN; PROSTATE SPECIFIC ANTIGEN; PTEN PROTEIN, HUMAN; TOLUENESULFONIC ACID DERIVATIVE; UBIQUITIN PROTEIN LIGASE;

ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DRUG RESISTANCE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MICE, NUDE; NITRILES; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; RNA INTERFERENCE; TOSYL COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; UBIQUITIN-PROTEIN LIGASES;

EID: 84934324687     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3526     Document Type: Article

References (42)

1. Schmidt LJ, Tindall DJ. Androgen receptor: past, present and future. Curr Drug Targets. 2013; 14:401-407.
2. Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 2014; 33:2815-2825.
3. Izumi K, Mizokami A, Lin WJ, Lai KP, Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 2013; 182:1942-1949.
4. Richter E, Masuda K, Cook C, Ehrich M, Tadese AY, Li H, Owusu A, Srivastava S, Dobi A. A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer. Epigenetics. 2007; 2:100-109.
5. Dobi A, Sreenath T, Srivastava S. Androgen-Dependent Oncogenic Activation of ETS Transcription Factors by Recurrent Gene Fusions in Prostate Cancer: Biological and Clinical Implications. In: Wang Z. Androgen-Responsive Genes in Prostate Cancer-Regulation, Function and Clinical Applications. New York: Springer Science 2013:307-328.
6. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
7. Kantoff PW, Mohler JL. New developments in the management of prostate cancer. J Natl Compr Canc Netw. 2013; 11:653-657.
8. Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, Zhang A, Xia X, Ilkayeva OR, Xin L, Ittmann MM, Rick FG, Schally AV, et al. Androgens regulate prostate cancer cell growth viaan AMPK-PGC-1amediated metabolic switch. Oncogene. 2014; 33:5251-5261.
9. Wong YN, Ferraldeschi R, Attard G, de Bono J. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol. 2014; 11:365-376.
10. Bastos DA, Dzik C, Rathkopf D, Scher HI. Expanding androgen-and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Oncology (Williston Park). 2014; 28:693-699.
11. Fahrenholtz CD1, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc Natl Acad Sci USA. 2014; 111:1084-1089.
12. Li B, Lu W, Chen Z. Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less. Receptors Clin Investig. 2014; 1. doi: 10.14800/rci.122.
13. van der Steen T, Tindall DJ, Huang H. Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci. 2013; 14:14833-14859.
14. Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001; 61:2892-2898.
15. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 2002; 21:4037-4048.
16. Xu LL, Shanmugam N, Segawa T, Sesterhenn IA, McLeod DG, Moul JW, Srivastava S. A novel androgenregulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics. 2000; 66:257-263.
17. Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res. 2003; 63:4299-4304.
18. Masuda K, Werner T, Maheshwari S, Frisch M, Oh S, Petrovics G, May K, Srikanta V, Srivatava S, Dobi A. Androgen receptor binding sites identified by a GREF_GATA model. J Mol Biol. 2005; 353:763-771.
19. Li H, Xu LL, Masuda K, Raymundo E, McLeod DG, Dobi A, Srivastava S. A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem. 2008; 283:28988-28995.
20. Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci USA. 2006; 103:15085-15090.
21. D'Antonio JM, Vander Griend DJ, Isaacs JT. DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer. 2009; 16:325-332.
22. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012; 44:685-689.
23. An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014; 6:657-669.
24. Jolliffe CN, Harvey KF, Haines BP, Parasivam G, Kumar S. Identification of multiple proteins expressed in murine embryos as binding partners for the WW domains of the ubiquitin-protein ligase Nedd4. Biochem J. 2000; 35:557-565.
25. Yang B, Kumar S. Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with distinct physiological functions. Cell Death Differ. 2010; 17:68-77.
26. An H, Krist DT, Statsyuk AV. Crosstalk between kinase and Nedd4 family ubiquitin ligases. Mol Biosyst. 2014; 10:1643-1657.
27. Rae FK, Hooper JD, Nicol DL, Clements JA. Characterization of a novel gene, STAG1/PMEPA1upregulated in renal cell carcinoma and other solid tumors. Mol Carcinog. 2001; 32:44-53.
28. Giannini G, Ambrosini MI, Di Marcotullio L, Cerignoli F, Zani M, MacKay AR, Screpanti I, Frati L, Gulino A. EGFand cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer. Mol Carcinog. 2003; 38:188-200.
29. Brunschwig EB, Wilson K, Mack D, Dawson D, Lawrence E, Willson JK, Lu S, Nosrati A, Rerko RM, Swinler S, Beard L, Lutterbaugh JD, Willis J, et al. PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. Cancer Res. 2003; 63:1568-1575.
30. Watanabe Y, Itoh S, Goto T, Ohnishi E, Inamitsu M, Itoh F, Satoh K, Wiercinska E, Yang W, Shi L, Tanaka A, Nakano N, Mommaas AM, et al. TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad proteins from active participation in TGF-beta signaling. Mol Cell. 2010; 37:123-134.
31. Singha PK, Yeh IT, Venkatachalam MA, Saikumar P. Transforming growth factor-beta (TGF-beta)-inducible gene TMEPAI converts TGF-beta from a tumor suppressor to a tumor promoter in breast cancer. Cancer Res. 2010; 70:6377-6383.
32. Hu Y, He K, Wang D, Yuan X, Liu Y, Ji H, Song J. TMEPAI regulates EMT in lung cancer cells by modulating the ROS and IRS-1 signaling pathways. Carcinogenesis. 2013; 34:1764-1772.
33. Vo Nguyen TT, Watanabe Y, Shiba A, Noguchi M, Itoh S, Kato M. TMEPAI/PMEPA1 enhances tumorigenic activities in lung cancer cells. Cancer Sci. 2014; 105:334-341.
34. Hirokawa YS, Takagi A, Uchida K, Kozuka Y, Yoneda M, Watanabe M, Shiraishi T. High level expression of STAG1/PMEPA1 in an androgen-independent prostate cancer PC3 subclone. Cell Mol Biol Lett. 2007; 12:370-377.
35. Liu R, Zhou Z, Huang J, Chen C. PMEPA1 promotes androgen receptor-negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21 Cip1 signaling pathway. J Pathol. 2011; 223:683-694.
36. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007; 128:129-139.
37. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007; 128:141-156.
38. Beltran H, Rubin MA. New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res. 2013; 19:517-523.
39. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol. 2004; 18:2409-2423.
40. Qi H, Grenier J, Fournier A, Labrie C. Androgens differentially regulate the expression of NEDD4L transcripts in LNCaP human prostate cancer cells. Mol Cell Endocrinol. 2003; 210:51-62.
41. Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Ali A, Srinivasan A, McLeod DG, Yegnasubramanian S, Srivastava S, Dobi A, et al. Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer. Epigenetics. 2014; 9:918-927.
42. Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L, Osborn DJ, Rosner IL, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S, Cullen J, et al. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res. 2008; 14:758-763.